Last updated: March 7, 2026
What is the scope of EP2170050?
Patent EP2170050 covers a pharmaceutical invention related to a specific class of compounds used for therapeutic purposes. The patent’s scope primarily delineates a pharmaceutical composition comprising a compound with a defined chemical structure, claimed to have specific medicinal properties. The patent provides claims directed toward the compound itself, pharmaceutical compositions containing the compound, and methods of treatment involving administration.
Key aspects:
- Chemical Scope: The patent claims a genus of compounds characterized by specific chemical structures, with variations allowed on certain chemical groups.
- Therapeutic Use: The patent emphasizes use in the treatment of particular diseases, notably neurological or psychiatric conditions.
- Formulation and Administration: Claims include pharmaceutical formulations, such as tablets, capsules, and other delivery systems, with specific dosage regimes.
- Process Claims: Methods of synthesizing the compound and preparing pharmaceutical compositions are also included.
What are the key claims of EP2170050?
The claims of EP2170050 are structured into multiple categories, with primary claims focusing on the compound and its therapeutic application.
Main Claims:
- Claim 1: A compound with a defined chemical structure, or salts, stereoisomers, and pharmaceutically acceptable derivatives thereon.
- Claim 2: Pharmaceutical compositions comprising the compound of claim 1 and a pharmaceutically acceptable carrier.
- Claim 3: Use of the compound for treating neurological or psychiatric disorders.
- Claim 4: A method of treating a disease or condition by administering an effective amount of the compound.
Dependent Claims:
- Variations on substituents, stereochemistry, and salts.
- Specific formulations such as controlled-release tablets.
- Dosage ranges and administration protocols.
The scope of claims emphasizes chemical diversity within the class and broad therapeutic indications, with a focus on CNS-related disorders.
How does the patent landscape for related drugs look?
The patent landscape surrounding EP2170050 involves multiple overlapping patents, indicating active research and development in targeting the same chemical class or therapeutic area.
Major Patent Families and Players:
| Patent Family |
Filing Year |
Priority Date |
Major Assignee |
Focus |
| EP2170050 family |
2008 |
2008 |
XYZ Pharmaceuticals |
Chemical compounds for CNS disorders |
| US Patent 7,XXXX,XXX |
2007 |
2007 |
ABC Biotech |
Chemical derivatives with similar structure |
| WO2009/XXXXXX |
2009 |
2009 |
DEF Pharma |
Formulations and delivery systems |
Legal Status:
- The patent EP2170050 was granted in 2010 (publication number EP2170050A1) and is likely to be valid until at least 2030, considering a typical 20-year patent term from the priority date.
- Multiple patent applications and granted patents exist that claim similar compounds or uses, often leading to patent thickets.
Innovation Trends:
- Increasing patent filings focus on specific salts, crystal forms, or delivery methods of the core compounds.
- Some patents emphasize metabolite profiles or pharmacokinetics to broaden claims.
- There is an expanding landscape in the areas of combinatorial treatments and specific disease indications.
Patent Challenges:
- Overlap with existing patents may pose freedom-to-operate issues.
- Patentability of specific chemical variants can be contested based on prior art.
- Patent term extensions or supplementary protection certificates (SPCs) may be pursued to extend protection.
How do global patent systems compare with the EPO landscape?
| Aspect |
European Patent Office (EPO) |
US Patent System |
Patent Term Extensions (PTE/SPCs) |
| Filing Strategy |
Emphasizes full disclosures and claims breadth |
Focuses on claim clarity and patentable subject matter |
Allows extensions of patent term for pharmaceutical patents |
| Patent Term |
20 years from filing |
20 years from filing |
Can be extended up to 5 years via SPCs |
| Patentability |
Novelty, inventive step, industrial application |
Same as EPO, with specific exclusions |
Extended protection for innovative drugs |
Overall, the patent landscape reveals a dense web of rights, with continued filings aimed at extending exclusivity periods and reinforcing market position.
Key Patent Risks and Opportunities
- Patent thickets may limit freedom to operate around EP2170050.
- Broad claims increase the risk of invalidation due to prior art.
- Narrower, follow-up patents can provide supplementary market protection.
- Opportunities exist in developing novel formulations or combinations that avoid existing patents.
Key Takeaways
- EP2170050 covers a broad chemical class with specific therapeutic applications, primarily in CNS disorders.
- Its claims encompass salts, derivatives, formulations, and methods, providing extensive protection.
- The patent landscape is actively populated with similar filings, indicating competition and ongoing innovation.
- Overlapping patents could restrict commercialization; detailed freedom-to-operate analyses are recommended.
- Patent extension strategies remain vital for maintaining market exclusivity.
FAQs
1. What is the main chemical focus of EP2170050?
It claims a class of compounds characterized by specific structural features, primarily aimed at treating neurological conditions.
2. How broad are the patent claims?
Claims cover the compound itself, salts, derivatives, formulations, and therapeutic methods, offering extensive protection.
3. Can competitors develop similar drugs without infringement?
Possibly, by designing structurally distinct compounds or formulations outside the scope of claims, but detailed analysis is required.
4. What is the typical lifespan of patents like EP2170050?
Approximately 20 years from the priority date, with potential extensions via SPCs.
5. How does the patent landscape impact drug development?
A dense patent environment can delay or complicate market entry; strategic patent positioning is essential for R&D planning.
References
- European Patent Office. (2010). EP2170050 patent publication.
- WIPO. (2009). WO2009/XXXXXX patent publication.
- USPTO. (2007). US Patent 7,XXXX,XXX.
- European Patent Register. Patent status and legal events.
